Parkinson’s Disease is a disorder of the central nervous system that affects movement, often including tremors.
Nerve cell damage in the brain causes dopamine levels to drop, leading to the symptoms of Parkinson’s.
Parkinson’s often starts with a tremor in one hand. Other symptoms are slow movement, stiffness, and loss of balance.
Medications can help control the symptoms of Parkinson’s.
Parkinson’s Disease is a progressive disease of the nervous system marked by tremor, muscular rigidity, and slow, imprecise movement, chiefly affecting middle-aged and elderly people. It is associated with degeneration of the basal ganglia of the brain and a deficiency of the neurotransmitter dopamine.
Wiki Number: PW153
Diagnosis: Parkinson’s Disease (Very complex; please read the Wikipedia article.)
US Patients: 2-6X likelihood of dementia
World Patients: 6.2Mil&117,400 Deaths (2015)
Age Onset: Over 60, usually; unless “early-onset Parkinson’s”
Brain Area: Cell deaths among the subantia nigra leads to dopamine deficits; Cells die from proteins into Lewy bodies in the neurons
Symptoms: tremor, slowness(bradykinesia), stiffness(excessive muscle contraction) and postural instability(10% fall weekly)
Progression: As it progresses, poor decision-making, less impulse control, impaired recall, less control of attention
Causes: genetics, injuries, pesticides;brain lesions from strokes;alpha-synuclein protein in the brain buildup; 50% have hallucinations
Medications: L-DOPA; deep brain stimulation by microelectrodes reduces muscular symptoms;
Therapies: Imaging by MRI, T2* and SW;, neuromelanin-MRI; Diffusion, MRI; PET; SPECT; DaTSCAN is the only FDA approved way to distinguish.
4 CURRENT ARTICLES
The world-wide medical research
reports chosen for each diagnosis
Clicking each title opens the
PubMed article’s summary-abstract.
- Evaluating the neuroprotective activities of vinpocetine, punicalagin, niacin and vitamin E against behavioural and motor disabilities of manganese-induced Parkinson's disease in Sprague Dawley ratsby Karema Abu-Elfotuh on July 3, 2022
The current study investigated the neuroprotective activity of some drugs and nutriceuticals with antioxidant and anti-inflammatory potential on the pathogenesis of Parkinson's disease (PD). Rats were categorized into seven groups: Rats received tween80 daily for 5 weeks as a control group, MnCl(2) (10 mg/kg, i.p) either alone (group II) or in combination with vinpocetine (VIN) (20 mg/kg) (group III), punicalagin (PUN) (30 mg/kg) (group IV), niacin (85 mg/kg) (group V), vitamin E (Vit E) (100...
- Neural correlates of working memory and compensation at different stages of cognitive impairment in Parkinson's diseaseby Takaaki Hattori on July 3, 2022
Working memory (WM) impairment is one of the most frequent cognitive deficits in Parkinson's disease (PD). However, it is not known how neural activity is altered and compensatory responses eventually fail during progression. We aimed to elucidate neural correlates of WM and compensatory mechanisms in PD. Eighteen cognitively normal PD patients (PD-CogNL), 16 with PD with mild cognitive impairment (PD-MCI), 11 with PD with dementia (PDD), and 17 healthy controls (HCs) were evaluated. Subjects...
- Blood extracellular vesicles carrying synaptic function- and brain-related proteins as potential biomarkers for Alzheimer's diseaseby Chen Tian on July 2, 2022
INTRODUCTION: Objective and accessible markers for Alzheimer's disease (AD) and other dementias are critically needed.
- Real-world evaluation of osteoporotic fractures using the Japan Medical Data Vision databaseby Saeko Fujiwara on July 2, 2022
CONCLUSION: Several clinical and demographic factors were associated with a higher risk and odds of subsequent fracture. This may help to identify patients who should be prioritized for osteoporosis treatment.